BCD-217
- Generic Name
- BCD-217
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
Phase 3
Recruiting
- Conditions
- Melanoma (Skin)Melanoma Stage III
- Interventions
- Biological: anti-PD1Procedure: Excision of the primary lesionProcedure: Regional lymphadenectomy
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Biocad
- Target Recruit Count
- 410
- Registration Number
- NCT05751928
- Locations
- 🇧🇾
Healthcare Institution "Minsk City Clinical Cancer Center", Minsk, Belarus
🇧🇾Healthcare Institution "Vitebsk Regional Clinical Oncology Center", Vitebsk, Belarus
🇧🇾State Institution "Republican Scientific and Practical Center of Oncology and Medical Radiology named after A.I. N.N. Alexandrov", Lesnoy, Belarus
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Phase 3
Active, not recruiting
- Conditions
- MelanomaMelanoma Stage IIIMelanoma (Skin)Melanoma Stage IVMelanoma UnresectableMelanoma MetastaticMelanoma Advanced
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Biocad
- Target Recruit Count
- 270
- Registration Number
- NCT05732805
- Locations
- 🇷🇺
Limited Liability Company "Stepmed Clinic", Saint Petersburg, Russian Federation
🇷🇺Limited Liability Company "Strategic Medical Systems", Saint Petersburg, Russian Federation
🇷🇺LLC "AV medical group", Saint Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath